Printable Version 

Dear fellow investors,

In the aftermath of the influx of illegal drugs into the U.S. in the 1980s, former First Lady Nancy Reagan led a campaign against drug use called “Just Say No.” In 1994, while at Smith Barney, our pharmaceutical analyst did a branch tour because her research piece used the same title. Her recommendation was to stay away from investing in pharmaceutical stocks.

Her sell recommendation couldn’t have been more poorly timed. Beginning in 1994, the pharma stocks were a great place to invest for decades. Her pessimism about industry difficulties was well researched but had been deeply priced into the stocks. We took full advantage back then and loved our contrarian circumstance.

Ironically, in 2004, one of the stocks that looked the most interesting was Merck (MRK). They had created an extremely effective painkiller called Vioxx. However, they resisted a label that warned of the side effects and were forced to pull the product.

This time, the fears are related to losing patent protection on their most successful cancer treatment, Keytruda. Merck is as cheap today by almost any measure as it was when they were forced to shut down their best-selling drug!

Thanks to pressure from the new Trump administration, the pharmaceutical stocks look somewhat as deeply out of favor relative to the S&P 500 Index as they were in 1994. For political reasons, the new administration is looking to bring inflation down. The persistent inflation from the massive $12 trillion of U.S. Treasury borrowing done to get us through COVID-19 seemed to doom any reelection possibilities for President Biden. Therefore, President Trump wants to get Republican candidates elected in the midterm elections. To him, driving down drug prices (and oil prices) is the way to gain favor with voters.

It took me three weeks of political science classes in 1976 to switch from that major to economics. In my 45 years in the investment business, buying out of favor meritorious companies when the politicians are hassling them has been one of our lifeblood’s. Think banks in 2012 when politicians were Occupying Wall Street and mall REITs (nobody is going to stores anymore) in the 2020 COVID-19 shutdowns.

Let’s compare Merck to the S&P 500 Index by a few valuation methods over the decades:


Source: Bloomberg.


Source: Bloomberg.

Compared to most stocks, Merck is a bargain, and we are looking to take the most advantage of what we view as a major mispricing in the sector. 

Play The Long Game,

william smead.

William Smead

The information contained in this missive represents Smead Capital Management’s opinions, and should not be construed as personalized or individualized investment advice and are subject to change. Past performance is no guarantee of future results. Bill Smead, CIO, wrote this article. It should not be assumed that investing in any securities mentioned above will or will not be profitable. Portfolio composition is subject to change at any time and references to specific securities, industries and sectors in this letter are not recommendations to purchase or sell any particular security. Current and future portfolio holdings are subject to risk. In preparing this document, SCM has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources. A list of all recommendations made by Smead Capital Management within the past twelve-month period is available upon request.

©2025 Smead Capital Management, Inc. All rights reserved.

This Missive and others are available at www.smeadcap.com

We Advise Investors

Sign up to get our advice sent straight to your inbox.

Recent Missives

High Expectations of Delayed Home Ownership

For the past two years, the housing narrative has been dominated by a single number: the thirty-year mortgage rate. With rates remaining high relative to pandemic-era lows, consensus expectations imply homebuilding is a...

⟶ Keep Reading

Dancing with the Pretty Girls

I think about life a lot differently as a 42-year-old man than when I was younger. Junior high dances come to mind, particularly where there were two groups of guys: those that dance...

⟶ Keep Reading

Trapped in the Mineshaft

[...] Therefore, most investors are asking the question: Is this a great buying opportunity? Our experience in the stock market would argue that these stocks are trapped in the mineshaft. First, we are...

⟶ Keep Reading

3Q26 International Value Strategy Newsletter: Being Greedy When Mr. Market Doesn’t Understand

The year 2026 has shown that deeply out of consensus investments in the portfolio have continued to reward investors. Our banks and energy companies continue to lead investment performance as they have over...

⟶ Keep Reading

3Q26 U.S. Value Strategy Newsletter: Breaking the Fever

When I was a child, we were told, “Starve a cold and feed a fever.” This appears to us to be what is going on in the stock market as we enter the...

⟶ Keep Reading

Understanding the 10-Year Treasury: A Multifactor Framework

Headlines are popping up left and right about how high the 10-year Treasury yield has risen. While investors make decisions about what is the “right” longer-term cost of government debt, many journalists focus...

⟶ Keep Reading

We Advise Investors

Sign up to get our advice sent straight to your inbox.

Scroll to Top